so there's a chance for it, but i think the fireworks will come early to the high prices then we'll have to worry about whether or not the market gets sloppy as we get deeper into the year, but it will be a fun, wide range yet fagain for us with a lot of unknowns that we're going to have to deal with >> the unknowns and knowns and known unknowns happy new year, my friend. that does it for us on the exchange i will join rahel solomon for "power lunch," which by the way, begins now welcome to "power lunch. as stocks look to close out 2021 at record highs, are there still cheap stocks out there that you can pick up at a discount? plus, a strong year for the healthcare sector. we're going to dig into the names that can continue their

streaks and the themes that will dominate 2022. and raise a glass. shares of duck up since their ipo. we'll speak with the ceo about the evolving alcohol industry, challenges for 2022 and emerging competition as one of the few public pure play wine companies. all that and more. >> thank you very much by the way, hi, i'm brian sullivan and here's where the markets stand right now. the dow is trying, trying to extend its winning streak to five days. right now, we're up about 113 points the nasdaq is down more than half a percent so this kind of rotation we've seen sort of tech into value, industrials, materials, maybe continuing today now, the s&p, it is down 0.1 if we close at an all-time high, it would be the 70th boeing is the best performer in the dow today. indonesia lifting a nearly three-year ban on the 737 max

following the deadly crash late in 2018. >> and stocks dip from new records. volatility apparently the name of the game again as concerns over the omicron variant really shakes up wall street. now, historically, value stocks have performed better than growth stocks in the face of market volatility, so let's bring in sarratt, managing partner at dcla. always good to have you. so you say that you feel that the markets will reward companies that have a significant margin of safety what names do you like >> so, in that sense, i like companies with you know, that have a growth area in front of them right now and they can increase margins as well for example, jnj trading at 16 times earnings 60% of its earnings come from the pharma group, 30% from med tech and they're spinning out their consumer group part. it has a higher growth than the

s&p. aaa balance sheet. 2.5% dividend yield and really growth coming forward with a margin of safety, given where we are in the growth cycle, where the fed is, where inflation is, these are good things to have for a company that can protect itself from the downside >> a lot of analysts feel that way. no sells on jnj. what's your time horizon how long do you think value sort of stays in favor? >> i think value's going to be here nofor a little bit we've had ten years of growth where the s&p has grown 16% a year and most of that has been grown by -- we're looking to f a value bend in our portfolio. yeah, i want growth at a reasonable price, but also growth that the market's underappreciating. you look like a jnj that trades at 20% discount to the market. so i think there are plenty of these opportunities abound

we've just had an area from the index has been taken over by megacap stocks >> you say you like budweiser. an area that also is seeing some growth >> so, here's a true value stock. this is a company that was broken it's a combination of many mergers. it's got a huge debt on top of it new management and really what's happening here is management is committed to growing kind of the key products they have eight of the ten top beers in the world 60% of their earnings come from emerging markets and they're trading at 18 times earnings, but 18 times might sound high, but it's very depressed earnings once consumers come back to restaurants and on premise takes over, not just in the u.s., but globally, this company has a huge runway ahead of it. people are looking to -- alcohol. constellation brands has done really well. this is a value play in an area that we see secular growth that has plenty of self-help

opportunity. >> what about concerns any concerns about rates rising too quickly next year? >> so, i think that's one of the reasons when we're looking for companies with safety, if rates do rise, you've got a couple of things going on. firstly, the companies that have discounted cash flow that have more cash flow in the future, you'll see more rotation out of them secondly, money will go into fixed income so you want to make sure you have fixed income substitutions in the equity market that people will not take money out of so jnj, budweiser, good companies with dividends also because you want companies that have their own tailwind behind them. >> i want to circle back to budweiser. alcohol in general seems to be a very competitive field these days you have coca-cola and pepsi entering the space any concerns competitively >> so, i think you're definitely going to have that, but one of the things that bud has is it's not a commodity alcohol.

if you look at their brands like stella, corona outside the u.s., they're able to hold price in fact, budweiser outside of the u.s. sells at a multiple at what it sells here that's where you can get operating lev rerage. you've got brand, cost savings and a management that's focused to growing as opposed to k looing inward and saying how do we just grow our earnings. i think the opportunity's here for a budweiser and the market is growing because more and more are looking for their own kind of consumer services they're looking for experiential and i think this fits right in there. >> you have growing demand amidst the pandemic for alcohol consumption. it's another story all together. thank you. brian. >> this isn't coffee actually, it is. chip stocks are pulling back today but they have still had a great run this year even though

the main story was about a chip shortage nvidia is up 130%. market cap is three quarters of a trillion dollars, so can the chips keep rolling in to 2022? josh, what say you, the folks you're talking to about the semiconductor space? >> so, brian, let's start with the smh. that is etf that tracks in today's trade, but we know it's been hitting records here and now up more than 40% this year under the hood of that etf, big moves in 2021. like nvidia, as you mentioned. amd and on semi just to name a few. chip investors know demand has been strong. on earnings calls, chip executives sound very positive and governments around the world that clearly recognize chips as a priority yes, shortages provided a tailwind for the sector, rasgon says there's a growing risk that

some customers have now purchased more than they actually need and won't order as much of course going forward. he says his checks indicate that's particularly true for autos and pcs, so he tells me he has buys in what he considers safety plays like broadcom with its attractive valuation and record backlog and qualcomm and nvidia, where he says results couldn't be better >> we're not done with you yet, josh so stacy rasgon is a little cautious, but what about other analysts do they share his concerns >> well, dr. rasgon has covered the semis for a long time. i did talk to chip brysonat wedbush. he would say he agrees with stacy. certain areas, matt says certain signs of inventory building and other areas though, he says you

still see these shortages, these real supply demand and balances like in networking, in power management chips that's why he tells me he still likes certain foundries. umc and global foundries he thinks those are still smart bets here. >> josh, appreciate it coming up, feeling fine. the healthcare sector closing out the year at all-time highs will the healthy returns continue next year and if so, where should you be invested plus, phase one of the china-u.s. trade deal coming to a close and while it's fallen short, there's been one big win. that story ahead and here's a look at some names hitting new 52-week or all-time highs today. they include crown castle, united health, cerner and gilead sciences back after this.

inner voice (sneaker shop owner): i'm surprising my team with a preview of the latest sneaker drop. because i can answer any question about any shoe. but i'm stumped when it comes to payroll. intuit quickbooks helps you easily run payroll in less than 5 minutes... ...so you can stay... one step ahead.

every day in business brings something new. ...so you can stay... so get the flexibility of the new mobile service designed for your small business. introducing comcast business mobile. you get the most reliable network with nationwide 5g included. and you can get unlimited data for just $30 per line per month when you get four lines or mix and match data options. available now for comcast business internet customers with no line-activation fees or term contract required. see if you can save by switching today. comcast business. powering possibilities.

welcome back to "power lunch. i guess bitcoin missed santa's sleigh because the losses continue as it falls below $50,000. just yesterday, i was onset talking to brian about how it was holding steady about 50,000. ether is also down about 7% right now. bitcoin and ether largely move in tandem with the s&p 500, but that relationship seems to be changing in december because the s&p 500 is up 5% while bitcoin

down 17% month to date but ether is up well over 400% and bitcoin is up about 63% on the year right now, there's no major catalyst there's a few things out there, but crypto linked stocks are following suit you've got american bitcoin miner, digital, down double digits all in the red back over to you guys. >> thank you very much the healthcare sector hitting a high today back to its inception in 1998. it is up 25 this year. it's slightly underperforming the s&p 500. top performing stocks are moderna, even though it's been weak lately, it's had a big year west pharma, lili and pfizer moderna up 130%. my next guest says its large cap outperformance could continue, but bio tech may be the weakest link in the sector joining us now is jared.

it's no surprise the vaccine makers are on the list i want to get your take on that, but before the stock picks, can you answer very basic question, two of them? i think a lot of our viewers have is this covid shock going to be an annual thing in your mind and how much money do the companies make from each shot? they're free to us, but somebody's paying. >> those are two difficult questions. i've sort of given up trying to predict the pathway of the pandemic from multiple standpoints and the boosters are an annual injection is probably one of them. it probably makes sense for another year, maybe two. i would be very surprised personally if we were sitting here in a couple of years and we were still getting this annual shot unless it maintained the

strength or severity it's maintained for two years it seems like this omicron variant is also dwindling in terms of how strong it is and what the health concerns are so i'd be very surprised if we were more than one or two years out from not really talking about this much at all hopefully. and then the second question in terms of how much money these companies are making, they priced these vaccines anywhere from 25 all the way up to about 65 or $70. pfizer shares, biontech, moderna is on its own. we have a couple of others jnj and astrazeneca. it really depends on the manufacturer and the geography the u.s. is paying the most, as usual, then it kind of goes from there. >> so, moderna, 65, 75 bucks, whatever, multiplied by billions or hundreds of billions. if it keeps going, it's going to be a lot of revenue. what about novavax

there's a lot about how it will not only get its vaccine approved, but it may be more devel developed for omicron or other variants after that. what's your take >> well, it's tough to understand beyond omicron where it really sits or where anyone sits given the fact you don't know if and when or where the next variant is coming from. regarding the company specifically, they still yet to be approved in the u.s they've gotten go ahead in some other geographies. but the issue for the company might be at this point that you know, so much of the u.s. has been vaccinated already. omicron is making its way through many people who have been vaccinated and boosted, so the real market opportunity for the company might be in these international regions where pricing is not as powerful we'll see, but given the fact that moderna and pfizer have dominated so far and biontech

obviously, it remains to be seen where it will fit. >> your best picks heading into next year. leave us with a little opportunity. >> i still like the cro space. these are stocks that help out bio pharma in terms of drug development and trials iqv, clr ctlt, i think these are all very well situated for what is probably going to be another big year in terms of bio tech and pharma innovation. both in the public and the private realm. so i think those stocks are all set to perform pretty well taking a fresh look at med tech, just given the fact the stocks have underperformed so names like striker could come back if and when we return to procedure standpoint then bio tech has been such an

underperformer we have not seen this sort of disparity in the history of the index. so i think there's some opportunity there, too >> yeah, listen, we forget, and i hate to say it, there's a lot of bad stuff out there that's not named covid. we haven't talked about it for two years, but cancer rates are up obesity rates are up let's end on a high note happy new year thank you. see you in 2022. >> thanks. appreciate it. >> brian, thank you. coming up, drink up. shares of duck horn portfolio are up more than 30% as consumer demand for wine jumps. we'll speak with the ceo about the future, the covid challenges and changing beverage landscape. and a look at wall street's top bets "power lunch" is back after this

growing up in a little red house, on the edge of a forest in norway, there were three things my family encouraged: kindness, honesty and hard work. over time, i've come to add a fourth: be curious.

be curious about the world around us, and then go. go with an open heart, and you will find inspiration anew. viking. exploring the world in comfort. here's your cnbc news update at this hour the state department is condemning today's move by russia's highest court to shut down that country's oldest human rights group calling on authorities there to end what it calls the harassment of independent voices. several protestors outside the courthouse were arrested after the ruling

the group memorial has been studying and reporting on government repression in the former soviet union. the court said memorial is creating what it calls a false image of the ussr as a terrorist state. france is reporting almost 180,000 new covid infections in a single day that's far above the previous record of around 105,000 set on saturday cases in the uk also hit a new pandemic high today. and with immense demand for covid testing around the united states, this testing site in massachusetts kept going even after it was hit by a car. the driver was hospitalized with minor injuries no one else was hurt luckily the cause of the crash is still under investigation. i hope they all got their tests. back to you. >> dramatic scene there. not the way that you want, but kudos to those healthcare workers for going on it's what they do. one holdover for the trump administration that president biden has left in place is not a person it is the trade deal with china. even though china's fallen short

on some areas, one reason u.s. officials are sticking with the plan, a win for farmers. kayla has more on what it means for the future of that deal. kayla. >> hey, brian. by the end of this year, the u.s. and china must certify that both sides are complying with the deal and the amount of chi chinese purchases from american farmers is one reason why it could be economically and politically painful to exit the deal under the terms, beijing pledged to buy $41 billion in agricultural goods in 2020 and $48 billion in 2021. last year's numbers fell short during the pandemic, but this year's ag exports to china are on track to come close to reaching the goal according to usda figures now, in the last year, american ag experts to china are up 38% due to both higher demand and higher prices. although there is some disagreement between experts about how much credit the deal gets for those increases

the u.s. soybean export council says walks out of -- in a big way. current will, the u.s. is dominating the soy imports the university of missouri says weather and african swine fever are also part of the equation. but notes china has bumped up its meat purchases in post trade wartimes, american farmers have seen their biggest customer base restored after two careers of uncertainty >> want to switch gears. reports just coming out this afternoon saying that president biden may nominate sarah bloom raskin for a position at the fed, which would make her effectively a top, or the top, banking regulator. what can you tell us >> i can tell you that according to my sources over the last several weeks, her name has been

in the mix as a contender for one of the many open spots on the board of governors, but because she sat on the board previously, my sources believed she would not rejoin the fed unless it was in a more senior role like that one you mentioned. the vice chair for supervision, the fed's lead bank regulator. the being said, the white house in recent weeks was also considering former cfpb head, rich cordray, but he was seen as a favorite of progressives on capitol hill remains to be seen exactly when and whether a final decision on that role and the others will be made the white house had said they would make an announcement before the holidays. that so far has not happened >> thank you very much and ahead on "power lunch," cathie wood goes on a selling spree. we'll look at some of the moves she's making plus, as new jersey continues to hit record covid cases, some hospitals are taking extreme measures to make sure patients get the treatment they need.

that story ahead (swords clashing) -had enough? -no... arthritis. here. aspercreme arthritis. full prescription-strength? reduces inflammation? thank the gods. don't thank them too soon. kick pain in the aspercreme. ♪ ♪ ♪ digital transformation has failed to take off. because it hasn't removed the endless mundane work we all hate. ♪ ♪ ♪

automation can solve that by taking on repetitive tasks for us. unleash your potential. uipath. reboot work. your record label is taking off. but so is your sound engineer. you need to hire. i need indeed. indeed you do. indeed instant match instantly delivers quality candidates matching your job description. visit indeed.com/hire small businesses like yours make gift-giving possible. m now, comcast business hason. an exclusive gift for you. introducing the gift of savings sale. for a limited time, ask how to get a great deal for your business. and get up to a $500 prepaid card with select bundles

when you switch to the network that can deliver gig speeds to the most businesses. or get started with internet and voice for $64.99 per month with a 2-year price guarantee. give your business the gift of savings today. comcast business. powering possibilities.

and commodities. plus, we'll talk to the ceo of a publicly traded winemaker. first, let's begin with the markets. bob pisani with those details. bob. >> and we had an all-time high take a look at the s&p 500 right after the open around 10:00 a.m. 4807 intraday high. but you see in the middle of the day around 12:30 eastern time, we had a classic sell program go through. somebody came in and sold a lot of s&p 500 index funds moved to the downside right across the board tech stock, defensive stocks, industrials, materials didn't matter. just the whole market took a 15 points lower we're scraping along on the bottom the good news is we're at new highs. but what's at new highs? it's not terribly inspiring, but it's there these are mostly defensive names. proctor and gamble, united health names like exelon. some utilities are at new highs.

mcdonald's are at new highs. you don't see many tech names. the few you see at new highs, they're all semiconductor stocks the smh hit a new high and we've got names like terradyne they're all down because they sold off when that 12:30 classic sell program came through the day. here's the good news you look at the s&p 500. we're at new highs that's good news the bad news is we're pretty overbought at this point you see that move to the right side straight nup the last five days this morning at 10:00 a.m., we moved about 240, almost 250 points in five days. that's almost 5% that's an awful lot to move going into the close so we have essentially overbought at this point going into 2022. the question is is that going to pull forward some of the gains that we might have seen in the early part of january. that's kind of what everybody's debating right now

guys, back to you. >> thank you and bond yields falling today. still can't crack that 1.5 level for the ten-year rick santelli tracking the bond market from chicago. rick >> yes, you know, there's been so many interesting features today. we started off this morning with the kay schiller numbers prices all around the country for housing. what we noticed for housing is the year-over-year home price index, well, it came in less at 19.08, but it's the fourth month in a row over 19%. it shows how sticky this housing inflation pricing pressures can be and if we look at a month to date of two-year note yield, another fresh high going back to march 2nd of 2020. it closed at .90 90 basis points. so we're going to be comping that for a while as you see on that chart but tens to two spread month to date, another fresh 13-month

flat hovering. if you look at a two-day of tens, right at 1:00 eastern, rates popped a bit because we had another messy treasury auction. 57,000,000,005 didn't go well just like yesterday's two-year with respect to demand and if we look at what's going on overseas, here's a month to date of bund yields they continue to firm up as we go right into year end and one thing i want to point out that the inflation issues we're discussing, well, europe seems to be avoiding addressing them and it seems as though the market is doing the job for them back to you. >> interesting rick, thank you. oil closing for the day. let's get the closing numbers from pippa at the commodity desk >> more green today for oil as omicron fears continue to subside. other crude is finishing well below its highs of the day wti is up .6% at $76.05.

earlier today, it hit $76. the contract crossing above its 50-day moving average for the first time since november 24th a gain of half of one percent. later today, we'll get inventory day from the american petroleum i institute. analysts survey are expecting a five million barrel crude draw back to you. >> thank you and as we get ready to raise a glass to a new year, let's get a check on the state of the luxury wine business here first on cnbc is alex ryan, chairman, ceo, and president of duck horn portfolio. a publicly traded wine company that's popped 30% since its ipo in march alex, thank you for being with us we know demand, we've talked about it, demand for alcohol has sort of surged during the pandemic

can't imagine why. i wonder what some of the supply chain issues you hear some about, if you had to raise prices >> happy holidays and thanks for having me on no, we're a luxury product concerned with the long-term we have a very measured approach to price increases over time, reflecting the quality and the great skill going into each bottle of wine so we're not going to be reactionary to the current environment. on a supply side, we've been able to navigate with a very diversified supply chain model or cost input, so we're hitting our margins and we're confident heading into the upcoming year or so of some supply uncertainty. we think we're going to be able to deliver products to our customers without major interruption >> and alex, i want to continue with supply chain issues because i would love for you to drive home the point how you've been able to get around the supply

chain issues we've even heard other distributors talk about. you have shortages of glass. of containers, of truck drivers. you have labor shortages you have with most of your vineyards in california and washington, you have weather concerns walk us through how you've been able to circumvent these issues. >> really, it's been 40 years in the practice in the making, but we have a very diversified raw inputs grapes obviously throughout california, washington as you mentioned a really diversified in many, many -- >> okay, so we lost alex ryan, but hopefully we'll get back to him because we want to hear more about those supply chain issues and there's a fun little talker, brian, about how that company is using sort of the voice activated devices that a lot of us have in our homes such as alexa, the google devices, to

sort of provide a virtual wine tasting. which i know about you, but certainly had my interest, so we're going to try to get him back up and running. >> we already had that just yell across the room, somebody get me a drink. that's called voice activated ordering here's the thing about alex ryan he's a wine guy. he is not a wall street guy. he started from high school. 1988 think about that high school, 1988. and all of a sudden, they're the only ones producing merlot, well, he's back now, so i can ask him. i was just about to compliment you, but now that you're here, i can't do that. you guys really did something nobody else did. you started producing merlot when no one gave a you know what about merlot in california it was all about cabernet. how has the industry changed and how have you guys evolved with it >> oh, you know, when we started, there were only about

40 or 50 wineries in napa valley now there's well over 400. competition has been good for us it's kept us on our toes forces us to make better merlot each year. so we love the competition it's invited new consumers into the luxury wine space throughout california and especially in napa valley. so the evolution has been great for the customer we believe that the competition will continue to provide better products in luxury wine for customers worldwide and i think that to your point, merlot in napa valley was put on the map in the last 40 years and we're a significant part of that, so we're excited about the future of luxury wine >> i want to touch on the consumer a bit i saw a story yesterday about lu luxury champagne prices surging 34% in the last year i wonder if you're seeing new consumers perhaps to the brand as some other types of alcohol become really expensive.

>> yeah, it's unfortunate. i think what happened to some of the champagne producers in europe, so i hope they get back on track with some better weather in the future. but it has translated into some consumers trying some sparkling wines in california and some of our other products people have to make choices and some of those radical price increases are tough to swallow from time to time. so i think that wherever there's disruption, there's opportunity as well. >> brian was sort of giving you kudos for being in the business for so long and working your way up from high school. you've certainly been in the industry for a long time, but i imagine that the ability to innovate even in a wine business is really important and so duck horn has an agreement or sort of a voice activated program, a virtual wine tasting of such tell us about how that works can i sort of scream out to alexa and get a glass of wine or how does it work exactly >> yeah, but alexa's going to

have to bring it to you, too we have a couple of steps. we've hooked up with alexa, and that's been exciting virtual tastings zoom has allowed us to bring wine country to people all over the world throughout the pandemic and it will continue into the future. i think innovation's two ways. one, how we touch the consumer, which you alluded to, which is great. the other are new products the pandemic was a great time to hunker down and create some new products and ideas and we did a tremendous amount of that. we're starting to see the fruits of those efforts our customers expect new and interesting things from time to time we delivered a ton of them last year and we'll take the next couple of years to get into full distribution some of my favorites are right next to me awaiting lunch, but in the meantime, innovation is alive and well at duckhorn and throughout the luxury wine business >> we'll leave it there. profits up 18% year-over-year.

brian. >> i'm told greenling is pretty good here's what's coming up on "power lunch." forget about retail stuff. are there any retail stocks that are worth your hard earned cash? plus, we're checking on today's big movers including this mystery stock which is having a very good december look at that chart study it focus. what could it be make your guesses. the answer's ahead don't be shy, now. i like that prime cut. -aflac! -i love my gold jacket, but that aflac blue feels so right. when you feel right, you coach right. i know that's right! prime never believed in double coverage, but health insurance and aflac...is money. ♪ must be the money ♪ and i know how coach prime feels about money. -aflaaaac. -♪ aaahhhh ♪ now that is what this jacket needs. ♪ must be the money ♪ get help with the expenses health insurance doesn't cover.

at aaflac.com

welcome back to "power lunch. we've been tracking the trades of cathie wood and her ark investment's etfs throughout the year and yesterday, we saw ark lighten its position in some of its largest holdings though the company notes they were in conjunction with etf distribution activity, which it did complete bloc, coinbase and zoom video were all part of the el issing and since the start of december, all of those names are down big. bloc is tracking for its worst month since march of 2020.

coinbase and unity are down 17% in the same period those declines have ark's funds under pressure as well the innovation fund off 40% of its february high. i'll send it over to you >> thank you very much it is time now for the power movers here we go evgo shares are down while the analyst is bullish the company's long-term future, they say wall street expectations are too high krispy kreme, that stock cont continuing to rise up 20% the month of december struggling to get back to those first big levels by the way, that was your mystery chart. let's take a look at some other names that went public this year sweetgreen, allbirds, and toast. they're all down today and since their debut. not a lot of appetite for some of the new names >> despite this being "power

lunch. can't imagine. thank you. total number of covid cases. things are worse than ever during the pandemic and especially in new jersey, hospitals are understaffed are they in danger of being overwhelmed? we'll get the full story next on "power lunch." i need indeed. indeed you do. indeed instant match instantly delivers quality candidates matching your job description. visit indeed.com/hire

♪♪ at cdw we get your teams work in different places, in different ways and across countless different networks. so how do you get everyone on the same page? microsoft surface devices, orchestrated by cdw. they adapt to each user and deliver multi-layered security, so your workforce gets seamless experiences wherever they roam. for devices that fit your unique workforce, trust microsoft surface and it orchestration by cdw. people who get it. trust microsoft surface and it orchestration by cdw. (soft music) hey dad, i'm about to leave.

don't forget your hat . good morning. how can i help? i need help connecting with my students. behind every last minute save, ok, that works. and holiday surprise, thank you! a customer service rep is working unseen, making it happen. and at genesys, we're proud to help them help you everyday.

let's talk covid cases are surging around the country. new jersey hit especially hard with cases jumping 120%. seven-day hospitalization rate up 29% luckily not nearly as much let's talk more about this and try to cut through some of the noise, the headlines and get perspective on how hospitals are holding up the president and ceo of holy name, a hospital in new jersey amount of patients hospitalized has doubled ndin the past weeks. if you follow me on twitter, they know i try to dig through the data on this the headlines can be scary, but sometimes, they are just wrong or misleading. i want to ask you some direct questions and i know some might be uncomfortable number one is this i've talked to three er doctors at three different hospitals

about what an admission is when you define a hospital admission at holy name, is that something that's admitted for something, they test positive later, they're admitted because they have covid and that's the main reason or because they've tested positive and they're so freaked out that they're having panic attacks? i've talked to two doctors about this as well what do you define as a covid admission? >> for us, because we have the ability to test very quickly now is someone who presents with symptoms, with an acute enough illness confirmed positive, covid positive, when they're in the er, admitted, and treated and usually released in a very short order. >> okay so these are people when you say admitted, but they're admitted for those symptoms but i think you know what i'm talk about, michael there is some confusion. there was a doctor in the uk today who's saying we've got to be careful on the data because if you come in with a broken leg

and test positive later, it goes under covid admission. did you think there's not great enough standardization of data because on this side of the desk, it's confusing >> yes, i think we need to improve and learn from a lot of the mistakes and the lessons along the last two years in how we classify and categorize the definitions in terms of the data and the statistics that we report so for us a covid admission is someone who is presenting with all the covid symptoms not the broken leg and maybe covid positive and so you have to have the symptoms, tested positive. we treat you for those symptoms and release you. >> this is uncomfortable there's a new york city said that 359% jump in pediatric admissions i'm a parent of a 7-year-old scary headline i went into the numbers and

found out the 395% which is getting the headlines is a jump from 22 to 109 kids in a city of 1.7 million chirp. i want no kids in the hospital what i'm saying is percentages can be sometimes misleading. tell us what you're seeing on the ground right now because some of these headlines are ter terrifying parents. >> that is a great tragedy and just not right that data like that is being touted in the headlines. we have seen an increase to me everybody, especially in new york area, has to kept it in perspective. we had 300 patients here we had over 100 people at one point on ventilators

it was a completely different environment than today so we were down to zero. we thought we had this behind us in the summer we went down to zero no covid patients in the hospital and creeped up and today with the recent uptick we are up to 59 that is a far cry from the 300 we had over a year ago so we have to keep it in perspective the disease is not -- the people are not presenting in this severe acute state that they were a year ago. yes, they are sick, feverish, have respiratory distress. and two thirds of patients in the hospital today and not just holy name. two thirds are unvaccinated. the third are breakthrough cases, the vaccine is old or

your body had a different reaction they are risk mitigators they limit the potential to have severe disease right? but absolutely does not limit your ability to get the disease. and so we've seen the effectiveness of the vaccine but the volume is nowhere near what the headlines make you believe it's busy. nowhere near where it was. >> it is busy and wonder are you having staffing issues i have a good friend who's a nurse. holy name. a really good friend who's a name not in new jersey. completely overwhelmed and feels like not enough nurses working in the unit to alleviate that pressure and i wonder if you see the same issues. >> workforce issues in health care started before the recent surge. after the are burnt out. there's other factors going on

staffing was a challenge before the recent surge we had close to 100 employees test positive and be out good news is we are shortening that isolation time and bringing them back sooner most of them are asymptomatic. they don't have -- all employees are vaccinated and so they're testing positive because they were travel or family for the holidays and thought it would be safe and surprised the tests are positive isolating them for five days and bringing them back to work safe. so that is a factor. we are worried i'm worried about the long term impact on the health care workforce overall. this is straining on them and need to be mindful of there. >> thank you best wishes to you and the holy family community. >> thank you. buying opportunities in

retail in 2022 stay with us you could be working with someone outside your company and wait for back and forth e-mail, or a call to be rescheduled for the third time. orrr... you could use slack. and work faster with everyone you work with, together in one place. slack. where the future works.

thinkorswim® by td ameritrade is more than a trading platform. it's an entire trading experience. with innovation that lets you customize interfaces, charts and orders to your style of trading. personalized education to expand your perspective. and a dedicated trade desk of expert-level support. that will push you to be even better. and just might change how you trade—forever. because once you experience thinkorswim® by td ameritrade ♪♪♪ there's no going back.

while the deceust is yet to settle for holiday retailers we look ahead to 2022 courtney regan has that. hi, courtney. >> hi. all the nuances that differentiate the retailers means lots of opinions to the stocks to be buying opportunities but i scoured the lists and have top picks for

2022 let's take a look at the casualization of the workplace that theme at home or in the office along with brand strength and solid direct to consumer businesses has lululemon and nike as top retail plays for 2022 capri holdings is top pick that's the parent of michael kors and others. it's reined in the inventory and promotions and will not revert back to discounts even if competitors do ubs have walmart and amazon on the top picks for 2022 list. both have underperformed this year and ubs says the stocks are mispricing some e-commerce positive impact. bath & body works is a publicly traded company and matt boss says the pandemic accelerated market share and foot traffic in store and gave pricing

opportunities so positioning bbwi well for 2022 >> lots of picks there i want to ask you about macy's the stock more than doubled this year what are analysts saying there >> yeah. this is an interesting one while the mastercad pulse holiday sales data said it was a good season for the department stores, analysts differ on the opinions for the retailer. one says it's a top pick for the year forecasting to take share and grow thanks to the leadership in omnichannel and the focus on the younger consumers. ubs takes the opposite side negative on macy's with a sell rating and says it will continue to lose share to pure play online players as well as brands own websites leading to lower sales and that one is a

battleground and watch it closely in the year to come. >> for sure. thank you. >> all right everybody, thank you for watching "power lunch. rahel, it was a pleasure. >> let's not do this 4:00 or 5:00 in the morning. 2:00 is so much better. >> got 2:00 a.m. 2:00 p.m thank you. "closing bell" starts right now. ♪ thank you. welcome to "closing bell." i'm sara eisen a mixed session here on wall street dow outperforming. nasdaq down. s&p 500 is hugging the flat line if it closes higher that marks another record closing high. number 70 for 2021. >> you have been keeping count for us i'm wilfred frost. good afternoon lye from the new york stock exchange. utilities and consumer staples among the to